1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207. doi:10.1056/nejmoa2001316
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1
3. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020;413:116832. doi:10.1016/j.jns.2020.116832
4. Dorche MS, Huot P, Osherov M, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci. 2020;417:117085. doi:10.1016/j.jns.2020.117085
5. Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19 2. J Alzheimer Dis. 2020;76(1):3-19. doi:10.3233/JAD-200581
6. Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol 2020. 2020;16(11):633-644. doi:10.1038/s41582-020-0398-3
7. Al‐Sarraj S, Troakes C, Hanley B, et al. The spectrum of neuropathology in COVID‐19. Neuropathol Appl Neurobiol. 2021;47(1):3-16. doi:10.1111/NAN.12667
8. Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69. doi:10.1186/s13195-020-00640-3
9. Serrano-Castro PJJ, Estivill-Torrús G, Cabezudo-García P, et al. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia. 2020;35(4):245-251. doi:10.1016/j.nrl.2020.04.002
10. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;4422(20):1-11. doi:10.1016/S1474-4422(20)30308-2
11. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5
12. Jang H, Boltz DA, Webster RG, Smeyne RJ. Viral parkinsonism. Biochim Biophys Acta - Mol Basis Dis. 2009;1792(7):714-721. doi:10.1016/j.bbadis.2008.08.001
13. Das Sarma J. Microglia-mediated neuroinflammation is an amplifier of virus-induced neuropathology. J Neurovirol. 2014;20(2):122-136. doi:10.1007/s13365-013-0188-4
14. Desforges M, Le Coupanec A, Dubeau P, et al. Human coronaviruses and other respiratory viruses: Underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1):14. doi:10.3390/v12010014
15. Aravamudhan P, Raghunathan K, Konopka-Anstadt J, et al. Reovirus uses macropinocytosis-mediated entry and fast axonal transport to infect neurons. PLoS Pathog. 2020;16(2):e1008380. doi:10.1371/journal.ppat.1008380
16. Mishra R, Banerjea AC. Neurological Damage by Coronaviruses: A Catastrophe in the Queue! Front Neurol. 2020;11:565521. doi:10.3389/fimmu.2020.565521
17. Al-Harthi L, Campbell E, Schneider JA, Bennett DA. What HIV in the Brain Can Teach Us About SARS-CoV-2 Neurological Complications? AIDS Res Hum Retroviruses. 2020;Aug 10. Ep(On line ahead of print). doi:10.1089/aid.2020.0161
18. Hosseini S, Wilk E, Michaelsen-Preusse K, et al. Long-term neuroinflammation induced by influenza a virus infection and the impact on hippocampal neuron morphology and function. J Neurosci. 2018;38(12):3060-3080. doi:10.1523/JNEUROSCI.1740-17.2018
19. Landry K, Thomas AA. Neurological Complications of CAR T Cell Therapy. Curr Oncol Rep. 2020;22(8):83. doi:10.1007/s11912-020-00935-6
20. Huang X, Hussain B, Chang J. Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms. CNS Neurosci Ther. 2020;27(1):36-47. doi:10.1111/cns.13569
21. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-2273. doi:10.1056/NEJMra2026131
22. Najjar S, Najjar A, Chong DJ, et al. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. J Neuroinflammation. 2020;17(1):231. doi:10.1186/s12974-020-01896-0
23. Subramaniam SR, Federoff HJ. Targeting microglial activation states as a Therapeutic Avenue in Parkinson’s disease. Front Aging Neurosci. 2017;9:176. doi:10.3389/fnagi.2017.00176
24. Govindarajan V, De Rivero Vaccari JP, Keane RW. Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets. J Neuroinflammation. 2020;17(1):1-15. doi:10.1186/s12974-020-01944-9
25. Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain, Behav Immun - Heal. 2020;9:100163. doi:10.1016/j.bbih.2020.100163
26. Theoharides TC, Stewart JM, Hatziagelaki E. Brain “fog,” inflammation a nd obesity: Key aspects of neuropsychiatric disorders improved by luteolin. Front Neurosci. 2015;9(JUN):1-11. doi:10.3389/fnins.2015.00225
27. Yelland GW. Gluten-induced cognitive impairment (“brain fog”) in coeliac disease. J Gastroenterol Hepatol. 2017;32:90-93. doi:10.1111/jgh.13706
28. de Sousa Moreira JL, Barbosa SMB, Vieira JG, et al. The psychiatric and neuropsychiatric repercussions associated with severe infections of COVID-19 and other coronaviruses. Prog Neuro-Psychopharmacology Biol Psychiatry. 2020;106(January):110159. doi:10.1016/j.pnpbp.2020.110159
29. Kalim H, Pratama MZ, Mahardini E, Winoto ES, Krisna PA, Handono K. Accelerated immune aging was correlated with lupus-associated brain fog in reproductive-age systemic lupus erythematosus patients. Int J Rheum Dis. 2020;23(5):620-626. doi:10.1111/1756-185X.13816
30. Peña-Casanova J, Quiñones-Úbeda S, Gramunt-Fombuena N, et al. Spanish multicenter normative studies (NEURONORMA project): Norms for boston naming test and token test. Arch Clin Neuropsychol. 2009;24(4):343-354. doi:10.1093/arclin/acp039
31. Peña-Casanova J, Quiñones-Úbeda S, Gramunt-Fombuena N, et al. Spanish multicenter normative studies (NEURONORMA project): Norms for verbal fluency tests. Arch Clin Neuropsychol. 2009;24(4):395-411. doi:10.1093/arclin/acp042
32. Peña-Casanova J, Gramunt-Fombuena N, Quiñones-Úbeda S, et al. Spanish multicenter normative studies (NEURONORMA project): Norms for the rey-osterrieth complex figure (copy and memory), and free and cued selective reminding test. Arch Clin Neuropsychol. 2009;24(4):371-393. doi:10.1093/arclin/acp041
33. Peña-Casanova J, Quiñones-Úbeda S, Quintana-Aparicio M, et al. Spanish multicenter normative studies (NEURONORMA project): Norms for verbal Span, visuospatial Span, letter and number sequencing, trail making test, and symbol digit modalities test. Arch Clin Neuropsychol. 2009;24(4):321-341. doi:10.1093/arclin/acp038
34. Benedet M de J, Alejandre MÁ. TAVEC Test de Aprendizaje Verbal España-Complutense 2. a Edición (revisada). TAVEC Test Aprendiz Verbal España-Complutense 2 a Edición. Published online 2014. http://www.web.teaediciones.com/Ejemplos/TAVEC-Manual-Extracto.pdf
35. Ojeda N, del Pino R, Ibarretxe-Bilbao N, Schretlen DJ, Peña J. Montreal cognitive assessment test: Normalization and standardization for Spanish population. Rev Neurol. 2016;63(11):488-496. doi:10.33588/rn.6311.2016241
36. Spielberger RD, Gorsuch RL, Lushene RE. Manual STAI, Cuestionario de Ansiedad Estado Rasgo. Tea Ediciones. 1982;23(7):3-14.
37. Sanz J, Perdigón AL, Vázquez C. Adaptaci ó n espa ñ ola del Inventario para la Depresi ó n de Beck-II ( BDI-II ): 2 . Propiedades psicom é tricas en poblaci ó n general The spanish adaptation of Beck ’ s Depression Inventory-II ( BDI-II ): Clin y Salud. 2003;14(3):249-280.
38. Hernandez G, Garin O, Pardo Y, et al. Validity of the EQ–5D–5L and reference norms for the Spanish population. Qual Life Res. 2018;27(9):2337-2348. doi:10.1007/s11136-018-1877-5
39. Doyle KL, Woods SP, McDonald CR, et al. Verbal episodic memory profiles in HIV-Associated Neurocognitive Disorders (HAND): A comparison with Huntington’s disease and mesial temporal lobe epilepsy. Appl Neuropsychol. 2019;26(1):17-27. doi:10.1080/23279095.2017.1353993
40. Guedj E, Million M, Dudouet P, et al. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging. 2021;48(2):592-595. doi:10.1007/s00259-020-04973-x
41. Fontana IC, Bongarzone S, Gee A, Souza DO, Zimmer ER. PET Imaging as a Tool for Assessing COVID-19 Brain Changes. Trends Neurosci. 2020;43(12):935-938.
42. Kas A, Soret M, Pyatigoskaya N, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. Published online 2021:doi: 10.1007/s00259-020-05178-y. Online ahead of p. doi:10.1007/s00259-020-05178-y
43. Lima LCD, Miranda AS, Ferreira RN, Rachid MA, e Silva ACS. Hepatic encephalopathy: Lessons from preclinical studies. World J Hepatol. 2019;11(2):173-185. doi:10.4254/wjh.v11.i2.173
44. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. 2020;7(7):611-627. doi:10.1016/S2215-0366(20)30203-0
45. Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588-597. doi:10.1207/s15327752jpa6703_13
46. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord. 2009;119(1-3):1-8. doi:10.1016/j.jad.2009.04.022
47. Vasquez BP, Zakzanis KK. The neuropsychological profile of vascular cognitive impairment not demented: A meta-analysis. J Neuropsychol. 2015;9(1):109-136. doi:10.1111/jnp.12039
48. Kempuraj D, Ahmed ME, Selvakumar GP, et al. Brain Injury–Mediated Neuroinflammatory Response and Alzheimer’s Disease. Neuroscientist. 2020;26(2):134-155. doi:10.1177/1073858419848293
49. Martins-Filho RK, Zotin MC, Rodrigues G, Pontes-Neto O. Biomarkers related to endothelial dysfunction and vascular cognitive impairment: A systematic review. Dement Geriatr Cogn Disord. 2020;130:365-374. doi:10.1159/000510053
50. Ramani S, Berard JA, Walker LAS. The relationship between neurofilament light chain and cognition in neurological disorders: A scoping review. J Neurol Sci. 2021;420. doi:10.1016/j.jns.2020.117229
51. Soldner D, Greiner S, Drummer D, Steinmann P, Mergheim J. Spatiotemporal Variations of Vascular Endothelial Growth Factor in the Brain of Diabetic Cognitive Impairment. Pharmacol Res. 2020;163:105234. https://doi.org/10.1016/j.addma.2020.101676